Translational success of fundamental virology: a VSV-vectored Ebola vaccine
Journal of Virology · 2024
DOI: 10.1128/jvi.01627-23 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Virology, 2024. Verfasst von Elizabeth M Anderson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Ebola Vaccines, Ebolavirus, Genetic Vectors, Hemorrhagic Fever, Ebola. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Ebola virus disease (EVD) caused by Ebola virus (EBOV) is a severe, often fatal, hemorrhagic disease. A critical component of the public health response to curb EVD epidemics is the use of a replication-competent, recombinant vesicular stomatitis virus (rVSV)-vectored Ebola vaccine, rVSVΔG-ZEBOV-GP (ERVEBO). In this Gem, we will discuss the past and ongoing development of rVSVΔG-ZEBOV-GP, highlighting the importance of basic science and the strength of public-private partnerships to translate fundamental virology into a licensed VSV-vectored Ebola vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, New Jersey, USA.
ORCID-Profile: Elizabeth M Anderson, Beth-Ann G Coller
Zitieren
APA
Anderson, E. M., & Coller, B. A. G. (2024). Translational success of fundamental virology: a VSV-vectored Ebola vaccine. Journal of Virology. https://doi.org/10.1128/jvi.01627-23
Vancouver
Anderson EM, Coller BAG. Translational success of fundamental virology: a VSV-vectored Ebola vaccine. Journal of Virology. 2024. doi:10.1128/jvi.01627-23
BibTeX
@article{Anderson2024,
author = {Anderson, Elizabeth M and Coller, Beth-Ann G},
title = {Translational success of fundamental virology: a VSV-vectored Ebola vaccine},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.01627-23}
}
EUVIMED